External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience ICNMD 2024
Roche and Genentech at

ICNMD 2024

October 25 - October 29
Perth, Australia
icnmd.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
11:00 PM
Duration 90mins Perth, Australia
Long-term comparative efficacy and safety of risdiplam▼ versus nusinersen in children with Type 1 SMA
E Sideris, N Hawkins, R Evans,C Gasser,A Mahajan, D Alexander Scott,C.S Sutherland,C Kokaliaris
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Perth, Australia
Muscle MRI Outcomes in Delandistrogene Moxeparvovec-Treated Patients With Duchenne Muscular Dystrophy From EMBARK Part 1
K Vandenborne, Walter, V Straub, R Willcocks, S Forbes, S Ennamuri, K Ding, C Reid, A Murphy, M Manfrini, J S Elkins, L R Rodino-Klapac
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:30 AM
Duration 15mins Perth, Australia
Safety and Efficacy of Delandistrogene Moxeparvovec Versus Placebo in DMD: Phase 3 EMBARK Primary Results
JR Mendell, F Muntoni, C McDonald, E Mercuri, E Ciafaloni, H Komaki, C Leon-Astudillo, A Nascimento, C Proud, U Schara-Schmidt, A Veerapandiyan, C M. Zaidman, M Guridi, A Murphy, C Reid, C Wandel, D R. Asher, E Darton, S Mason, R A Potter, T Singh, K Ding, P Fontoura, J S Elkins, L R Rodino-Klapac
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:30 AM
Duration 15mins Perth, Australia
RAINBOWFISH: 2-year efficacy and safety data of risdiplam▼ in infants with pressymptomatic SMA
R S Finkel, M A Farrar, L Servais, D Vlodavets, E Zanoteli, M Al-Muhaizea, A PQC Araújo, L Nelson, B Jaber, K Gorni, H Kletzl, L Palfreeman, E Gaki, M Rabbia, D Summers, P Fontoura, E Bertini
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:00 AM
Duration 15mins Perth, Australia
Long-term comparative efficacy and safety of risdiplam▼ versus nusinersen in children with Type 1 SMA
E Sideris, N Hawkins, R Evans,C Gasser,A Mahajan, D Alexander Scott,C.S Sutherland,C Kokaliaris
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.